Posted by Michael Wonder on 20 Jun 2017
Melinta Therapeutics announces U.S. FDA approval of Baxdela (delafloxacin) for acute bacterial skin and skin structure infections (ABSSSI)
19 June 2017 - Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as monotherapy.
Melinta Therapeutics announced today that the U.S. FDA has approved Baxdela (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.
Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus), and is available in both intravenous and oral formulations.
